FTC OKs Sun's Taro Buy After Divestitures
United States antitrust regulators have challenged Sun Pharmaceutical Ltd.'s proposed acquisition of its generic drug manufacturing competitor Taro Pharmaceutical Industries Ltd., claiming the deal may result in higher prices for generic...To view the full article, register now.
Already a subscriber? Click here to view full article